Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON

Toonaangevende leiders

Alle informatieOndernemingenMarktenEconomie & ForexgrondstoffenRenteToonaangevende leidersFinanciŽle professionalAgendaSectoren 
HomepaginaAl het nieuwsHet meest gelezen nieuwsBiografieŽn van de Leiders
Portrait de Fred Ehrenkranz Cohen
Leeftijd : 63
Vermogen : 13 739 875 USD
Belangrijkste bedrijven : Intellia Therapeutics, Inc. - Progyny, Inc. - CareDx, Inc - UroGen Pharma Ltd.
Overzicht 
Founder of 5 different companies, notably: Kyverna Therapeutics, Inc., TPG Biotechnology Partners LP and Cell Design Labs, Inc. Fred Ehrenkranz Cohen is an entrepreneur and presently holds the position of Senior Managing Director at VV Manager LLC (which he founded in 2017), Chairman for Cell Design Labs, Inc. (which he founded in 2016) and Managing Director & Partner at Tarrant Capital IP LLC.

He is also Member of American Academy of Arts & Sciences, Member of Institute of Medicine, Member of Association of American Physicians, Member of American Society for Clinical Investigation and Member of National Academy of Medicine and on the board of 14 other companies.

He previously was Director at Rapid Micro Biosystems, Inc., Senior Director-Business Development at Kosan Biosciences, Inc., Managing Director at The Plastics Group, Inc., Managing Director & Partner at TPG Biotechnology Partners LP (he founded the company in 2001), Senior Managing Partner at Vida Ventures LLC (he founded the company in 2017), Advisor at CHV Capital, Inc., Partner at TPG Capital LLC and Professor at The University of California, San Francisco.

Dr. Cohen received an undergraduate degree from Yale University, a doctorate from the University of Oxford and a doctorate from Stanford University.


Posities en verantwoordelijkheden van Fred Ehrenkranz Cohen 
NaamTitel Van
Intellia Therapeutics, Inc.
(Biotechnologie & Medisch Onderzoek)
Independent Director 2019
Progyny, Inc.
(Beheerde gezondheidszorg)
Independent Director 2015
CareDx, Inc
(Biotechnologie & Medisch Onderzoek)
Independent Director 2003
UroGen Pharma Ltd.
(Biotechnologie & Medisch Onderzoek)
Independent Director 2017
Cell Design Labs, Inc. Chairman 2016
Tarrant Capital IP LLC Managing Director & Partner 2013
Quintiles Transnational Corp. Director -
Acumen, Inc. Director -
UCSF Foundation Director 1987
Novotech (Australia) Pty Ltd. Director -
Matrix Pharmaceuticals, Inc. Director -
Autistica Trustee -
Kyverna Therapeutics, Inc. Director -
Acrostar Pharmaservices Corp. Director 2017
Novotech Aus Holdco Pty Ltd. Director 2018
Novotech Health Holdings Ltd. Non-Executive Director 2020
American Academy of Arts & Sciences Member 2008
Institute of Medicine Member 2004
Association of American Physicians Member 1995
American Society for Clinical Investigation Member 1990
National Academy of Medicine Member -
VV Manager LLC Co-Founder and Senior Managing Director 2017


Belangnemingen van Fred Ehrenkranz Cohen 
NaamAandelen%Totale waarde
CareDx, Inc (CDNA)
(Biotechnologie & Medisch Onderzoek)
107 0200,20%7 842 426 USD
Intellia Therapeutics, Inc. (NTLA)
(Biotechnologie & Medisch Onderzoek)
32 0940,044%5 152 050 USD
Veracyte, Inc. (VCYT)
(Biotechnologie & Medisch Onderzoek)
10 0000,014%481 100 USD
UroGen Pharma Ltd. (URGN)
(Biotechnologie & Medisch Onderzoek)
15 0000,067%264 300 USD
Progyny, Inc. (PGNY)
(Beheerde gezondheidszorg)
00,0000%0 USD


Fred Ehrenkranz CohenPersoonlijk netwerk 
Meest gelezen nieuws 
15/09BRAD SMITH : Microsoft kondigt inkoop van eigen aandelen aan tot $60 mrd, verhoogt dividend
MR
13/09MARTIN SORRELL : Sorrell's S4 Capital verhoogt winstverwachting tot 40%
MR
14/09STEPHEN SCHERR : Goldman Sachs benoemt Coleman als nieuwe CFO, ter vervanging van Scherr
MR
15/09ILHAM KADRI : Activist Bluebell Capital wil ontslag CEO Solvay
AM
Meer nieuws


© 2021 People and Ownership :   
Fred Ehrenkranz Cohen Verbindingen